glp-1 drugs for sleep apnea Efficacy of Receptor agonists in treating Obstructive apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes Will GLP-1 Drugs Disrupt the

Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib AdCV, Bellicieri FN, Lima Hdo, Ho AMH, dos Anjos GS, de Moura DTH, de Moura EGH, Vieira JE

The most common adverse effects from the SURMOUNT trials include: Nausea: 24-33% of participants (dose-dependent) Diarrhea: 18-25% of participants Constipation: 13-17% of participants Vomiting: 8-12% of participants Decreased appetite: 10-15% of participants Most of these effects are mild to moderate and occur primarily during dose escalation periods

These studies reveal that the pharmacology profile of tirzepatide is not only determined by the peptide sequence, but also the location and composition of the acyl side chain

A recent randomized and double-blind trial revealed that, for adults with poorly controlled T2DM, oral semaglutide at total doses of 25 mg and 50 mg was more effective than the 14-mg total dose in reducing HbA1c and body weight (33)